Morphosys Licenses Antibodies to Proteomika for Use in Companion Dxs | GenomeWeb

German biotech firm Morphosys said this week its ABd Serotec division has licensed seven of its diagnostic HuCAL antibodies to Spanish biomarker company Proteomika for use in its Promonitor diagnostic.

Promonitor is designed to determine circulating levels of different drugs and the immune response they trigger in patients.

It plans to launch kits in the second quarter of this year containing the HuCAL antibodies that can help monitor certain biopharmaceutical therapies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.